ENTRY       hsa01523                    Pathway
NAME        Antifolate resistance - Homo sapiens (human)
DESCRIPTION Since the 1940s, antifolates have played a pivotal role in drug treatment of malignant, microbial, parasitic and chronic inflammatory diseases. The molecular basis of the anti-proliferative activity of antifolates relies on inhibition of key enzymes in folate metabolism, which results in disruption of purine and thymidylate biosynthesis, inhibition of DNA replication and cell death. The anti-inflammatory properties of antifolate have been most strongly related to its ability to block the release of pro-inflammatory cytokines such as tumour necrosis factor (TNF)-alpha or interleukin (IL)-1beta. Cells may develop resistance to an antifolate drug by virtue of impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells.
CLASS       Human Diseases; Drug resistance: antineoplastic
PATHWAY_MAP hsa01523  Antifolate resistance
DRUG        D10954  Mirvetuximab soravtansine (USAN/INN)
            D11447  Arfolitixorin (USAN/INN)
            D12183  Farletuzumab ecteribulin (USAN)
            D12528  Arfolitixorin sulfate (JAN)
            D12880  Pasifolate exatecan (USAN)
ORGANISM    Homo sapiens (human) [GN:hsa]
REFERENCE   PMID:22921318
  AUTHORS   Gonen N, Assaraf YG
  TITLE     Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
  JOURNAL   Drug Resist Updat 15:183-210 (2012)
            DOI:10.1016/j.drup.2012.07.002
REFERENCE   PMID:17333344
  AUTHORS   Assaraf YG
  TITLE     Molecular basis of antifolate resistance.
  JOURNAL   Cancer Metastasis Rev 26:153-81 (2007)
            DOI:10.1007/s10555-007-9049-z
REFERENCE   PMID:26920997
  AUTHORS   Municio C, Soler Palacios B, Estrada-Capetillo L, Benguria A, Dopazo A, Garcia-Lorenzo E, Fernandez-Arroyo S, Joven J, Miranda-Carus ME, Gonzalez-Alvaro I, Puig-Kroger A
  TITLE     Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis.
  JOURNAL   Ann Rheum Dis 75:2157-2165 (2016)
            DOI:10.1136/annrheumdis-2015-208736
REFERENCE   PMID:24732946
  AUTHORS   Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD
  TITLE     Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
  JOURNAL   Nat Rev Clin Oncol 11:282-98 (2014)
            DOI:10.1038/nrclinonc.2014.51
REFERENCE   PMID:18297517
  AUTHORS   Fotoohi AK, Albertioni F
  TITLE     Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.
  JOURNAL   Leuk Lymphoma 49:410-26 (2008)
            DOI:10.1080/10428190701824569
REFERENCE   PMID:17203006
  AUTHORS   van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G
  TITLE     Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside.
  JOURNAL   Nat Clin Pract Rheumatol 3:26-34 (2007)
            DOI:10.1038/ncprheum0380
REFERENCE   PMID:17092765
  AUTHORS   Assaraf YG
  TITLE     The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
  JOURNAL   Drug Resist Updat 9:227-46 (2006)
            DOI:10.1016/j.drup.2006.09.001
REFERENCE   
  AUTHORS   Mauritz R.
  TITLE     Determinants of antifolate and 5-fluorouracil efficacy
  JOURNAL   Biochemistry
REFERENCE   
  AUTHORS   del-Campo LS, Montenegro MF, Saez-Ayala M, Fernandez-Perez MP, Cabezas-Herrera J, Rodriquez-Lopez JN.
  TITLE     Cellular and molecular mechanisms of methotrexate resistance in melanoma
  JOURNAL   Intech
            DOI:10.5772/52414
REFERENCE   PMID:16380836
  AUTHORS   Walling J
  TITLE     From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.
  JOURNAL   Invest New Drugs 24:37-77 (2006)
            DOI:10.1007/s10637-005-4541-1
REFERENCE   PMID:22954694
  AUTHORS   Desmoulin SK, Hou Z, Gangjee A, Matherly LH
  TITLE     The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.
  JOURNAL   Cancer Biol Ther 13:1355-73 (2012)
            DOI:10.4161/cbt.22020
REFERENCE   PMID:16491071
  AUTHORS   Cheok MH, Evans WE
  TITLE     Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
  JOURNAL   Nat Rev Cancer 6:117-29 (2006)
            DOI:10.1038/nrc1800
REFERENCE   PMID:23987246
  AUTHORS   van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G
  TITLE     Methotrexate analogues display enhanced inhibition of TNF-alpha production in whole blood from RA patients.
  JOURNAL   Scand J Rheumatol 43:9-16 (2014)
            DOI:10.3109/03009742.2013.797490
REFERENCE   PMID:8793930
  AUTHORS   Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR
  TITLE     Intrinsic and acquired resistance to methotrexate in acute leukemia.
  JOURNAL   N Engl J Med 335:1041-8 (1996)
            DOI:10.1056/NEJM199610033351408
REFERENCE   PMID:15117425
  AUTHORS   Adjei AA
  TITLE     Pharmacology and mechanism of action of pemetrexed.
  JOURNAL   Clin Lung Cancer 5 Suppl 2:S51-5 (2004)
            DOI:10.3816/CLC.2004.s.003
REFERENCE   PMID:14576850
  AUTHORS   Zhao R, Goldman ID
  TITLE     Resistance to antifolates.
  JOURNAL   Oncogene 22:7431-57 (2003)
            DOI:10.1038/sj.onc.1206946
REFERENCE   PMID:21317831
  AUTHORS   Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB
  TITLE     PharmGKB summary: methotrexate pathway.
  JOURNAL   Pharmacogenet Genomics 21:679-86 (2011)
            DOI:10.1097/FPC.0b013e328343dd93
REFERENCE   PMID:23897011
  AUTHORS   Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL
  TITLE     Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.
  JOURNAL   Arthritis Rheum 65:2791-802 (2013)
            DOI:10.1002/art.38094
REFERENCE   PMID:11509639
  AUTHORS   Majumdar S, Aggarwal BB
  TITLE     Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation.
  JOURNAL   J Immunol 167:2911-20 (2001)
            DOI:10.4049/jimmunol.167.5.2911
REL_PATHWAY hsa00230  Purine metabolism
            hsa00670  One carbon pool by folate
            hsa04064  NF-kappa B signaling pathway
            hsa04144  Endocytosis
KO_PATHWAY  ko01523
///
